Benefits
Tension and stress scores over a 3 day trial
The entire intake period in the one human trial was 3 days, so a 3 day onset is simply the length of the study, not a demonstrated speed advantage. Tension scores on the Profile of Mood States (POMS) fell in every group measured against its own baseline, placebo included, so tension is not a clean result. Doses of 50, 100 and 150 mg were all tested.
Sleep quality enhancement (LSEQ)
In the single 3 day trial, sleep quality on the Leeds Sleep Evaluation Questionnaire (LSEQ) improved against placebo, and the difference showed up 24 hours after the first capsule at the lowest dose of 50 mg, not only above 100 mg. Participants also rated it easier to get to sleep, most so at 150 mg, and the 150 mg dose improved the morning wakefulness score by about 7 percent. LSEQ is a self-rated questionnaire, not a sleep recording, and nothing was measured past day 3.
Self-rated anxiety scores in adults with moderate anxiety
Everyone in this trial was recruited with moderate anxiety by design, scoring 18 to 24 on a modified Hamilton Anxiety Rating Scale (m-HAM-A), so this was not a group of otherwise unbothered adults. Group average scores fell over the 3 day intake at all three doses, and the 100 mg group average moved below the study cut-off; the paper reports an average, not that every participant crossed it. This is a 30 person pilot lasting 3 days and it is not evidence of treating an anxiety disorder.
Mood improvement and vigor
In the one 3 day trial, participants reported better sleep quality, mood, ease of falling asleep and easier morning waking, and vigor scores rose at the 100 and 150 mg doses. All of these are self-report questionnaire items collected 48 hours after the first capsule. No objective performance, alertness or physiological measure was taken, and nothing was followed beyond 3 days.
Endocannabinoid targets, shown in laboratory assays only
In test tube assays run by the manufacturer and published alongside the human trial, the extract inhibited CB2 receptor binding by 85.5 percent at a screening concentration of 200.3 micrograms per mL, and inhibited the FAAH enzyme by 92 percent in a separate assay at a single fixed concentration. The endocannabinoid system does help regulate stress responses, but these were isolated enzyme and receptor assays: no endocannabinoid marker was measured in any person, and a concentration in a dish tells you nothing about what a 100 mg capsule reaches in the body.
Multi-system CNS modulation
In the same laboratory assays the extract bound the serotonin 5HT1A receptor, showing 62.3 percent inhibition at 200.3 micrograms per mL. The GABA result was negative: 1 percent inhibition at the GABA-A binding site and 23 percent at the benzodiazepine site, which the authors report as no significant interaction. A GABA-based explanation is therefore not supported by the study this page relies on, and none of these receptor findings has been shown to happen in people.
Food-status culinary precedent
Grains of paradise is a long-standing kitchen spice in West and North African cooking, and FDA lists the seed among generally recognized as safe spices and flavorings at 21 CFR 182.10. That history covers the whole spice in cooking amounts. It is not safety data for a concentrated extract standardized to 10 percent vanilloids and taken daily as a capsule.
Mechanism of action
FAAH enzyme inhibition (endocannabinoid)
In a test tube assay the extract inhibited fatty acid amide hydrolase (FAAH) by 92 percent at a single fixed test concentration. FAAH breaks down anandamide, an endogenous cannabinoid involved in mood, stress regulation and sleep, so blocking it would in theory preserve anandamide signaling. This remains a proposed mechanism. Anandamide levels, FAAH activity and every other endocannabinoid marker went unmeasured in the people who took the extract, and no comparison with any medication has been made.
CB2 receptor modulation
In the same laboratory screen the extract produced 85.5 percent CB2 receptor binding inhibition at 200.3 micrograms per mL. CB2 receptors are part of the endocannabinoid system and are involved in stress, immune response and inflammation. The same screen also showed 56.6 percent binding inhibition at the CB1 receptor, so the extract was not CB2 selective in the dish. No receptor activity of any kind was demonstrated in people; participants in the 3 day trial reported no side effects.
Serotonergic system effects
In a radioligand assay the extract inhibited binding at the serotonin 5HT1A receptor by 62.3 percent at a single test concentration. Serotonin signaling matters for mood, sleep and stress, so the authors offer this as a possible partial explanation for the questionnaire changes seen over 3 days. No serotonin measurement was taken in any participant, so the link is a hypothesis.
GABA-A targets tested, no significant effect found
The GABA system was tested and the result was negative. In the published assays the extract inhibited only 1 percent of GABA-A binding and 23 percent at the benzodiazepine site, which the authors describe as no significant interaction. GABA is the main inhibitory neurotransmitter behind relaxation and sleep onset, but the sleep changes reported in the 3 day trial cannot be attributed to a GABA effect on this evidence, and no comparison with sedative medicines is warranted.
Vanilloid compound bioactivity
The 6-shogaol, 6-paradol and 6-gingerol vanilloids in Vanizem are structurally similar to capsaicin, the pungent compound in chili peppers. In the published laboratory assays the extract activated the TRPV1 receptor in a dose-dependent way. Whether TRPV1 has anything to do with the questionnaire changes seen in the trial was never tested, so treat this as a hypothesis rather than an explanation.
Clinical trials
Randomized, double-blind, placebo-controlled crossover pilot trial. Each participant took placebo and 50, 100 and 150 mg in sequence, each period lasting 3 days, with a 7 day washout between periods. Questionnaires were collected on day 1 and 48 hours after the first capsule of each period. Published in Pharmaceuticals 2025;18:278 (Pérez-Machín et al.). Independence: the trial was paid for by Nektium Pharma, which sells this extract as Vanizem; three of the six authors are Nektium employees, and the contract research firm that ran the human part was financed by Nektium.
45 adults screened, 37 randomized, 30 completed. Aged 40-50, 44 percent women. Entry required moderate anxiety, defined as 18 to 24 on the modified Hamilton Anxiety Rating Scale, so this was not a general healthy sample. Each dose was taken for 3 days.
Over each 3 day intake, average m-HAM-A anxiety scores fell at 50, 100 and 150 mg while placebo did not change, and the 100 mg group average moved below the study anxiety cut-off. That is a group average, not every individual. POMS tension fell in all four groups against their own baselines, placebo included, so tension is not a clean separation from placebo. On the LSEQ, sleep quality beat placebo 24 hours after the first capsule at the 50 mg dose, and ease of falling asleep improved most at 150 mg. No side effects were reported. This is a single 30 person pilot with no measurement after day 3.
Laboratory work, not a clinical trial. Radioligand binding and enzyme inhibition assays on receptor and enzyme preparations, reported in the same paper as the human trial. Nobody took the extract in this part of the work.
Not applicable — in vitro binding and inhibition assays on cellular and enzymatic targets.
In the binding screen at 200.3 micrograms per mL the extract inhibited CB2 binding by 85.5 percent, CB1 binding by 56.6 percent and 5HT1A binding by 62.3 percent, and it activated TRPV1 in a dose dependent way. A separate enzyme assay at a single fixed concentration showed 92 percent FAAH inhibition. The GABA-A assays were negative at 1 percent and 23 percent. A concentration in a dish is not a blood level, so none of these numbers tells you what a 50 to 150 mg capsule does in a person.
Animal research, not a clinical trial and not a study of Vanizem. Mouse behavior tests including the forced swim test, the unpredictable chronic mild stress paradigm, sucrose preference and tail suspension, using a seed extract of Aframomum melegueta rather than the branded microencapsulated extract sold as Vanizem. No source for this work appears anywhere in the reference list on this page.
Not applicable — preclinical mouse studies of antidepressant-like activity.
Reported results in mice were reduced immobility in the forced swim test at 25 to 50 mg/kg and less anhedonia and anxiety-like behavior after chronic mild stress. These are rodent screening tests, in a different species, with a seed extract that is not the branded product, at a dose given per kilogram of body weight that does not translate directly into a human capsule dose. They do not show an effect in people, and this page cites no reference for them at all.